Live
- India Faces Blow as Pacer Mohammed Shami Ruled Out for Remainder of Australia Series
- Biden Pardon: Joe Biden Commutes Death Sentences of 37 Inmates, Including Child Killers and Mass Murderers
- South Korea: Yoon believes impeachment trial takes priority over martial law probe
- Strict Action for Non-Adherence to Time Management - DMHO Dr. Swarajya Lakshmi
- Over 13.29 lakh houses approved for rural poor in Maharashtra: Shivraj Chouhan
- District Collector Urges Timely Completion of Indiramma Housing Scheme Survey
- Digital Arrest Scam: Hyderabad Man Duped of ₹7 Lakhs by Fake Crime Branch Police Callers
- Sukhbir Badal seeks President's Police medal for officer who saved his life
- US Firm Accordion Acquires Merilytics, Launches 1,500-Seater Office in Hyderabad
- Free Medical Camp Organized by Alampur Advocate Bar Association
Biovet to invest Rs 200 crores for facility expansion
Biovet Private Limited, an animal vaccine maker, announced that it would invest Rs 200 crore as part of its expansion plans to meet the growing market demand for the vaccine which tackles Foot & Mouth Disease (FMD) and Brucellosis in animals.
Hyderabad: Biovet Private Limited, an animal vaccine maker, announced that it would invest Rs 200 crore as part of its expansion plans to meet the growing market demand for the vaccine which tackles Foot & Mouth Disease (FMD) and Brucellosis in animals.
Biovet informed that it commenced the work towards expanding the FMD vaccine manufacturing facility in Malur, Karnataka.
Krishna Ella, Founder, Biovet, said: "Expansion of our FMD vaccine facilities to deliver 200 million doses is an important step to increase our contribution to meet the shortage of this vaccine in the country."
The company based in Bengaluru will construct a new Brucella Vaccine Production facility at the Malur site to produce 100 million doses.
The vaccine maker said that according to estimates, India's FMD control programme requires 1,000 million doses every year, whereas the current production capacity manufactured in the country is only around 500 million doses.
There is an unmet need for 500 million doses, and Biovet aims to fulfil this gap.
